SHP-1 mRNA在髓系白血病患者中的表达及临床意义  

Expression of SHP-1 mRNA in Patients with Myelogenous Leukemia and Its Clinical Significance

作　　者：刘学东 刘晓[2] 李英华[2] 张永晓[2] 李志赏[2] 

机构地区：[1]衡水市中心血站,河北衡水053000 [2]哈励逊国际和平医院血液科,河北衡水053000

出　　处：《中国实验血液学杂志》2017年第4期975-979,共5页Journal of Experimental Hematology

基　　金：河北省医学研究课题计划项目(ZD2014090)

摘　　要：目的:探讨造血细胞磷酸酶(SHP-1)信使核糖核酸(mRNA)在髓系白血病患者中的表达及其与治疗效果和慢性髓系白血病(CML)临床分期的关系。方法:54例CML患者,30例初诊急性髓系白血病(AML)患者,10例非恶性肿瘤常规查体者做对照组(CG),应用SYBR Green荧光定量PCR的方法,检测骨髓或外周血单个核细胞中SHP-1 mRNA的表达情况。结果:CG、慢性髓系白血病慢性期(CP-CML)、进展期CML、AML组SHP-1 mRNA的相对表达水平分别为:1.15±0.62,4.96±1.76,2.60±0.90,0.45±0.20。CML患者SHP-1 mRNA表达水平较CG组表达水平显著增高(P<0.05)。CML患者中,CP-CML患者的SHP-1 mRNA表达水平非常显著高于进展期CML患者(P<0.0001)。AML患者较CG组SHP-1 mRNA表达水平明显降低(P=0.0442)。CP-CML患者伊马替尼(IM)治疗3个月时的治疗反应理想组初诊时SHP-1 mRNA表达水平为5.712±0.4476,非常显著地高于反应不佳或失败组4.044±0.3701(P=0.0090)。AML患者诱导化疗达完全缓解组(CR)初诊时SHP-1 mRNA表达水平为0.4984±0.05164,高于未完全缓解组(non-CR)0.3537±0.02388(P=0.0017)。结论:CML患者SHP-1 mRNA表达水平高于AML患者,且与CML疾病进展相关;初诊时SHP-1 mRNA表达水平可以作为预测CP-CML对伊马替尼早期治疗反应及AML患者诱导化疗效果的指标。Objective： To investigate the expression and clinical significance of SHP-1 mRNA in patients with myelogenous leukemia. Methods： The SYBR Green-based qRT-PCR was used to assess SHP-1 mRNA levels in 54 patients with chronic myelogenous leukemia（ CML）,30 cases of de novo acute myelogenous leukemia（ AML） and 10 persons without malignancy as controls. Results： The relative expression levels of SHP-1 mRNA in control group（ CG）,chronic phase CML（ CP-CML） group,advanced phase of CML（ including accelerated phase CML and blastic phase CML） group and AML group were 1. 15 ± 0. 62,4. 96 ± 1. 76,2. 60 ± 0. 90 and 0. 45 ± 0. 20,respectively. The expression of SHP-1 mRNA in patients with CML significantly increased in comparison with that in CG（ P〈0. 05）.Meanwhile,the expression of SHP-1 mRNA in CP-CML group very significantly increased as compared with that in advanced stage of CML group（ P〈0. 0001）. The expression of SHP-1 mRNA in AML group significantly decreased as compared with that in CG group（ P = 0. 0442）. In CP-CML group,statistical analysis showed that SHP-1 mRNA expression at baseline in optimal responders（ 5. 712 ± 0. 4476） was significantly higher than that in the suboptimal or failed responders（ 4. 044 ± 0. 3701）（ P = 0. 0090）. Meanwhile,the SHP-1 mRNA expression in AML patients was higher than that in CR group（ 0. 4984 ± 0. 05164） and non-CR group（ 0. 3537 ± 0. 02388）（ P = 0. 0017）. Conclusion：The SHP-1 mRNA levels in CML patients are higher than that in AML patients,and probably correlats with disease progression of CML. The mRNA expression level of SHP-1 may be a molecular marker to predict early response to inatinib treatment in CP-CML and AML.

关 键 词：SHP-1 MRNA 髓系白血病 抑癌基因 疾病进展 

分 类 号：R733.7[医药卫生—肿瘤]